Expression of Cadherins in Luminal a Breast Cancer

Zasadkevich Y. M., Brilliant A. A., Sazonov S. V. 

GAHO SR Institute of Medical Cell Technologies;
GBEO HPE Ural State Medical University,
Yekaterinburg, Russian Federation

Abstract.

Expression of E-cadherin, P-cadherin, as well as associated molecules of β-catenin and p120-catenin in Luminal A breast cancer was studied. Thestudied group included 50 appropriated cases. Expression of E-cadherin and associated molecules on breast cancer cells was detected by immunohistochemical method with use of specific antibodies. In the majority of the cases (92 %) coexpression of E- and P-cadherins was found. Correlation between expression of both cadherins was r = 0.70 (p < 0.05). β- and p120-catenins, which associated with E- and P-cadherins, expressed in 64 and 88 % respectively. Correlation between the parameters was r = 0.58 (p < 0.05).
The appearance of β- andр120-cateninsexpressionsuggestsstartof signal pathways, activated by aberrant expression of epithelial cadherins that lead to increase of motility and invasion of breast cancer cells.

Keywords:

breast cancer, Luminal A subtype, E-cadherin, P-cadherin

REFERENCES
1. Perou C.M., Sorlie T., Eisen M.B. Molecular portraits of human breast tumours. Nature.-2000.- V.406.-N6797.-P.747-52.
2. Cheang M.C.U., Chia S.K., Voduc D., et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. J Natl Cancer Inst.-2009.-V.101.-N10.-P.736-750
3. SemiglasovV.F., Paltuev R.M., Semiglasova T.U. et al. Clinical recommendations in breast cancer diagnostics and treatment. ABC-press.-St. Petersburg.-2013.-238p.
4. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast cancer Study. JAMA.-2006.-V.295.-N21.-p.2492-2502.
5. Weigelt B., Peterse J.L., and van't Veer L.J. Breast cancer metastasis: markers and models. Nature reviews. Cancer.-2005.-Vol.5.-pp.591-602.
6. Li D.-M., Feng Y-M. Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets. Breast Cancer Res Treat.-2011.-N128.-P..7-21.
7. Paredes J., Figueiredo J., Albergaria A., et al. Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochimica et Biophysica Acta.-2012.-N1826.-P.297-311.
8. Albergaria A., Ribeiro A.S., Vieira A.F., et al. P-cadherin role in normal breast development and cancer. Int.J.Dev.Biol.-2011.-N55.-P.811-822.
9. Zasadkevich Y.M., Sazonov S.V. The Roleof E-cadherin cell adhesion molecule in human ontogenesis in norm and pathology. Morphology.-2014.-V.146.-N5.-p.78-82.
10. Kowalski P.J., Rubin M.A., Kleer C.G. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Research.-2003.-N5.-P.217-222.
11. Vieira A.F., Ricardo S., Ablett M.P. et al. P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in Basal-like breast cancer. Stem cells.-2012.-N30.-P.854-864.
12. Faria G., Cardoso M.J., Martins D., et al. P-cadherin as prognostic factor for loco-regional relapse in breast cancer. Acta Med Port.-2012.-V.25.-N2.-P.97-105.
13. Paredes J., Albergaria A., Oliveira J.T. et al. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res.-2005.-N11.-P.5869-5877.
14. Paredes J., Milanezi F., Viegas L. et al. P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast. Virchows Arch.-2002.-N44.-P.16-21.
15. Ikeda S., Fujimori M., Shibata S. et al. Combined immunochemistry of β-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer.-2006.-V.6.-N31.
16. Liu Y., Wang Y., Zhang Y., et al. Abnormal expression of p120-catenin, E-cadherin, and small GTPases is significantly associated with malignant phenotype of human lung cancer. Lung Cancer.-2009.-N63.-P.375-382.
17. Allred D.C., Harvey J.M., Berardo M. et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol.-1998.-N89.-P.111-117.
18. Hammond M.E., Hayes D.F., Dowsett M. et al. American Society of Clinical Oncology. College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J ClinOncol.–2010.-Vol.28.- P.2784-2795.
19. Bilous M., Dowsett M., Isola J., et al. Current perspectives on HER2 testing: a review of national testing guidelines. MolPathol.-2003.-N16.-P.173-182.
20. Wolff A.C., Hammond M.E., Schwartz J.N. et al. American Society of Clinical Oncology. College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J ClinOncol.–2007.-N25.-P.118-145.
21. Jalava P., KuopioT., et al. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology.-2006.-V48.-N6.-P.674-82.
22. Ribeiro A.S., Sousa B., Carreto L. et al. P-cadherin role is dependent on E-cadherin cellular context: a proof of concept using the breast cancer model. J Pathol.-2013.-N229.-P.705-718.

Authors
Zasadkevich Yulia M.
yulkat@bk.ru
PhD student, researcher
Brilliant Aleksandr A. 
alex_brilliant@mail.ru
PhD, senior researcher
Sazonov Sergey V.
prof-ssazonov@yandex.ru
PhD, professor, the Head of the department of histology, cytology and embryology of Ural State Medical University and the laboratory of pathomorphology of Institute of Medical Cell Technologies
Government Budget Educational Organization «Ural State Medical University» of Ministry of Healthcare of Russian Federation, Department of histology, cytology and embryology
620028 Repinastr.,3, Yekaterinburg, Russia
Government Autonomic Healthcare Organization of Sverdlovsk Region «Institute of Medical Cell Technologies»
620036, Soboleva str., 25, Yekaterinburg, Russia
imct@celltechnologies.ru